Back to Map
RECRUITING
Updated: May 18, 2025
Adult SMA Research and Clinical Hub (REACH)
Brief Summary
Adult SMA REACH is a data collection study aiming to gain a better understanding of the impact of standards of care and new treatments on the natural history of Spinal Muscular Atrophy (SMA). This study is sponsored by The Newcastle upon Tyne Hospitals NHS Foundation Trust. Adult SMA REACH is funded by Biogen and Roche.
Currently, there are three drug treatments available for SMA in the UK: Zolgensma, Nusinersen and Risdiplam. Zolgensma is the only approved drug - Nusinersen and Risdiplam are currently available as part of Managed Access Agreements (MAA).
Key Information
Participation Criteria
Study Design
Locations & Contacts
Inclusion Criteria:
- Age ≥16 years (when patients will begin the transition process to adulthood)
- Genetically confirmed diagnosis of 5q SMA
- Signed informed consent to take part in the study
Exclusion Criteria:
- Non-5q SMA
- No genetic confirmation
- <16 years of age
- No signed informed consent or consent withdrawn